Drug Profile
Research programme: mGluR2 modulators - Addex Pharmaceuticals/Ortho-McNeil
Alternative Names: ADX 92639; JNJ-40068782Latest Information Update: 28 Jan 2021
Price :
$50
*
At a glance
- Originator Addex Pharmaceuticals; Ortho-McNeil
- Developer Addex Therapeutics; IRCCS Neuromed Mediterranean Neurological Institute; Ortho-McNeil
- Class Antidementias; Antidepressants; Antipsychotics; Anxiolytics; Ischaemic heart disorder therapies; Small molecules
- Mechanism of Action Metabotropic glutamate receptor 2 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cognition disorders; Major depressive disorder; Stroke
- Discontinued Anxiety disorders; Schizophrenia
Most Recent Events
- 28 Jan 2021 No recent reports of development identified for preclinical development in Cognition-disorders in Italy
- 28 Jan 2021 No recent reports of development identified for preclinical development in Major depressive disorder in Italy
- 28 Jan 2021 No recent reports of development identified for preclinical development in Stroke in Italy